Copyright ©The Author(s) 2015.
World J Hepatol. Aug 18, 2015; 7(17): 2053-2057
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2053
Figure 1
Figure 1 Proposed algorithm for the management of the hepatocellular carcinoma patients who discontinue permanently Sorafenib, combining the results of studies evaluating reason of Sorafenib discontinuation of Iavarone et al[23] and Reig et al[22]. HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; RCTs: Randomized controlled trials.